04:39:11 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriLäkemedel & Handel
Herantis Pharma är ett forskningsbolag. Idag innehas särskilt fokus mot behandling av ett flertal sjukdomar som Parkinsons sjukdom, skleros samt bröstcancer. Bolaget innehar en produktportfölj som för närvarande befinner sig i olika kliniska faser. Bolaget kom till via en sammanslagning av Hermo Pharma och Laurantis Pharma och har sitt huvudkontor i Esbo.

Kalender

2022-08-25 Kvartalsrapport 2022-Q2
2022-04-22 Ordinarie utdelning HRTIS 0.00 EUR
2022-04-21 Årsstämma 2022
2022-03-03 Bokslutskommuniké 2021
2021-08-26 Kvartalsrapport 2021-Q2
2021-04-16 Ordinarie utdelning HRTIS 0.00 EUR
2021-04-15 Årsstämma 2021
2021-03-03 Bokslutskommuniké 2020
2020-12-02 Extra Bolagsstämma 2020
2020-08-27 Kvartalsrapport 2020-Q2
2020-04-09 Ordinarie utdelning HRTIS 0.00 EUR
2020-04-08 Årsstämma 2020
2020-02-27 Bokslutskommuniké 2019
2019-08-28 Kvartalsrapport 2019-Q2
2019-04-12 Ordinarie utdelning HRTIS 0.00 EUR
2019-04-11 Årsstämma 2019
2019-03-12 Extra Bolagsstämma 2019
2019-02-28 Bokslutskommuniké 2018
2018-08-29 Kvartalsrapport 2018-Q2
2018-04-12 Ordinarie utdelning HRTIS 0.00 EUR
2018-04-11 Årsstämma 2018
2018-03-02 Bokslutskommuniké 2017
2017-11-09 Extra Bolagsstämma 2017
2017-08-29 Kvartalsrapport 2017-Q2
2017-04-12 Ordinarie utdelning HRTIS 0.00 EUR
2017-04-11 Årsstämma 2017
2017-02-28 Bokslutskommuniké 2016
2016-08-25 Kvartalsrapport 2016-Q2
2016-04-12 Ordinarie utdelning HRTIS 0.00 EUR
2016-04-11 Årsstämma 2016
2016-02-25 Bokslutskommuniké 2015
2015-08-19 Kvartalsrapport 2015-Q2
2015-04-10 Ordinarie utdelning HRTIS 0.00 EUR
2015-04-09 Årsstämma 2015
2015-02-27 Bokslutskommuniké 2014
2014-04-23 Kvartalsrapport 2014-Q1
2014-03-05 Bokslutskommuniké 2013
2022-04-13 16:32:00

Herantis Pharma Plc, Company release, 13 April 2022 at 5:35 p.m. EEST

The Board of Directors of Herantis Pharma Plc ("Herantis") has on 13 April 2022 decided to grant a maximum of 168,041 option rights entitling to shares to certain members of the management team under the option rights program 2021 I. The option rights program is based on the authorization granted by the Annual General Meeting held on 15 April 2021 to issue a maximum of 975,000 option rights.

The Board of Directors has in April 2021 resolved on issuance of a total of 961,221 option rights under the option rights program 2021 I. However, 369,262 of the issued option rights have subsequently been returned to the company as a result of the termination of employment or service relationship of certain persons. The Board of Directors have therefore decided on issuance of these new option rights under the option rights program 2021 I and within the limits of the authorization granted by the Annual General Meeting held on 15 April 2021. The total number of option rights granted and outstanding under the option rights program 2021 I after this issuance is 775,000.

The option rights will be offered without consideration. Each option right entitles to subscribe for one ordinary share in Herantis for a subscription price of EUR 2.60 per share. The subscription price corresponds to 126% of the volume weighted average share price during 10 trading days preceding the grant date of 13 April 2022 (30 March 2022-12 April 2022). The subscription price is higher than the subscription price of the company's share in the company's latest share issue against consideration preceding the option grant date.

Granted share options shall vest and become exercisable over a three-year period, with 1/3 becoming exercisable from 13 April 2023, with an annual vesting of 1/3 during the second year after the grant date, and with an annual vesting of 1/3 during the third year after the grant date. The options expire on 13 April 2027 or earlier subject to customary conditions.

For more information, please contact:

Herantis Pharma Plc, Timo Veromaa, Chairman, telephone: +358 40 5739933

---------------------------------

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400

Company website: www.herantis.com

Herantis Pharma Plc

Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson's Disease. Herantis lead product HER-096, is an advanced small and synthetic chemical peptidomimetic version of the active parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the ability to be delivered to the brain via subcutaneous administration.

The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. For more information, please visit https://www.herantis.com.